

REVIEW OPEN



Cost-effectiveness of lung cancer screening: insights from risk stratification, guidelines, and emerging technologies—a systematic review

Zijuan Fan^{1,5}, Manqi Zheng^{1,5}, Ziyun Guan¹, Hanting Liu¹, Pengyue Guo¹, Yang Zhu¹, Bo Zhang¹, Luyao Hu¹, Xianqi Zhao¹, Tiantian Fu¹, Mengting Liu¹, Xinran Jiang¹, Ningjun Ren¹, Chunli Zhang¹, Wenxi Wang^{2✉}, Chun Hao^{1,3✉} and Jinghua Li^{4✉}

Lung cancer is the leading cause of cancer-related mortality worldwide, with most patients diagnosed at advanced stages. Early detection through screening can significantly reduce mortality, making cost-effectiveness evidence crucial for guiding policy decisions. This systematic review aimed to evaluate the cost-effectiveness of lung cancer screening across various modalities, populations, and settings. A comprehensive search of PubMed, EMBASE, Web of Science, and Cochrane Library was conducted for studies up to March 18, 2025, adhering to PRISMA guidelines. A total of 79 studies from 21 countries were included, with model-based analyses prevalent and 89.9% rated as high quality. Low-dose computed tomography (LDCT) emerged as the primary screening modality, although evidence on artificial intelligence (AI) and biomarkers is limited. Fourteen studies comparing LDCT with no screening showed incremental cost-effectiveness ratios (ICERs) ranging from \$8376 to \$200,921 per quality-adjusted life-year (QALY) gained. Notably, 90.3% of LDCT strategies were cost-effective by national thresholds, particularly in older adults and high-risk groups. Biennial screening often proved more cost-effective than annual in many scenarios. Overall, LDCT screening demonstrated favorable cost-effectiveness, necessitating further evaluation for emerging technologies in underserved regions.

npj Primary Care Respiratory Medicine (2026)36:15; <https://doi.org/10.1038/s41533-026-00482-w>

INTRODUCTION

Lung cancer (LC) is the leading cause of cancer-related mortality worldwide, accounting for approximately 2 million new cases and 1.76 million deaths annually¹. Alarming, nearly 75% of LC patients are diagnosed at an advanced stage, a factor strongly associated with poor prognosis^{2,3}. This underscores the critical importance of early detection strategies to improve outcomes.

Screening for LC has been emerged as a pivotal strategy to identify disease at earlier, more treatable stages, thereby reducing LC morbidity and mortality⁴. Two large randomized controlled trials, the National Lung Screening Trial (NLST) and the Netherlands Leuvens Screening Onderzoek (NELSON) trial, showed low-dose computed tomography (LDCT) screening reduces LC mortality by 20% compared to chest X-ray (CXR) and by 24% compared to no screening^{2,5,6}.

Given the promising health benefits, Many economic studies have examined the cost-effectiveness of LC screening to guide large-scale implementation^{7–10}. However, previous reviews focused only on LDCT screening, while other modalities like CXR are still commonly used for their lower cost and reduced radiation^{11,12}. New advances, such as artificial intelligence (AI), also show promise for improving different LC screening methods^{3,13,14}. To date, no reviews have comprehensively summarized and evaluated the cost-effectiveness of LC screening tools beyond LDCT, particularly with regard to emerging diagnostic approaches. Previous reviews have largely focused on LDCT, with literature searches conducted up to 2022, and limited databases^{7,10}. Costing studies can provide valuable information on intervention costs

that are essential for implementation. Given the scarcity of healthcare resources and the economic burden that scaling up LC screening may impose on individuals and society, a comprehensive and up-to-date review synthesizing the economic value of LC screening would help inform evidence-based policy and decision-making.

This systematic review aims to update and synthesis the evidence on cost-effectiveness of LC screening. We evaluated the methods and outcomes of existing economic studies, providing a comprehensive overview of the latest research to inform health policy decisions.

METHODS

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines¹⁵. The review protocol was prospectively registered in PROSPERO (CRD42024598581).

Search Strategy

A structured search was performed using the following Boolean terms: “Lung Cancer” AND “Screening” AND “Economic Evaluations”. The complete and reproducible search strategies for each database are available in eTables 1–4. We searched the electronic databases EMBASE, PubMed, Web of Science, and Cochrane Library from their inception through 18 March 2025. We also reviewed the reference lists of included papers and pertinent systematic reviews for further eligible articles.

¹Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou, China. ²The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China. ³Sun Yat-Sen Global Health Institute, Institute of State Governance, Institute of International and Regional Studies, Sun Yat-sen University, Guangzhou, China. ⁴Department of Public Health and Medicinal Administration, Faculty of Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macao SAR, China. ⁵These authors contributed equally: Zijuan Fan, Manqi Zheng. ✉email: danywxw@163.com; haochun@mail.sysu.edu.cn; lijinghua@um.edu.mo

Eligibility criteria

We included both comprehensive (cost-effectiveness, cost-utility, and cost-benefit analysis) and partial (cost analysis) economic analyses of LC screening. Both trial-based and model-based economic analyses were eligible. Trial-based analyses were defined as those using data exclusively derived from clinical trials to estimate costs and effectiveness. Model-based studies incorporated external sources of data beyond trial parameters, even if trial data informed model inputs such as intervention duration and sample size. No restrictions were applied on language, publication date or country. We excluded commentaries, editorials, letters, protocol paper, conference abstract, and systematic reviews of economic analyses.

The population of interest comprised individuals undergoing LC screening regardless of the screening modality used. Studies focusing solely on clinically diagnosed LC cases (e.g., via biopsy and mediastinoscopy) were excluded. Outcomes of interest included any health-related measures such as quality-adjusted life-years (QALYs), life year gained (LYG), and mortality reduction due to screening.

Study selection and data extraction

Following deduplication, two authors independently screened titles and abstracts, followed by full-text assessments to determine eligibility. Disagreements were resolved by consulting a third reviewer. All data extraction was performed independently and in a blinded fashion by the same two authors, with any discrepancies resolved by discussion.

Extracted information included: authors, publication year, country, type of economic analysis, risk prediction model used, cohort, screening tools, scenarios, study population, study design, type of economic analysis, cost year, time horizon, perspective of economic analysis, discount rate, measure of effectiveness, type of currency, detailed costs components (total costs, diagnosis and assessment costs, medical services and professional costs, treatment-related costs, and others), incremental cost-effectiveness ratio (ICER), sensitivity analysis. For studies lacking explicit cost years reporting, the cost year was calculated by subtracting two years from the publication year^{16,17}.

Risk of bias and quality appraisal

For model-based studies, the British Medical Journal checklist described by Drummond and Jefferson was used to assess the quality of the studies¹⁸. Studies were rated based on the presence of the following key elements: (1) description of the model type and analytic method; (2) transparency of data sources; (3) description of simulation components, including transition probabilities, health states utilities and costs, and related parameters and assumptions; and (4) assessment of uncertainty through appropriate sensitivity analysis. Studies satisfying all four criteria were classified as high quality; those failing to meet any single criterion were considered low quality¹⁷.

For trial-based studies, quality assessment was conducted using version 2 of the Cochrane Risk of Bias Tool for Randomized Trials¹⁹, the Newcastle–Ottawa Scale (NOS)²⁰, and the Agency for Healthcare Research and Quality (AHRQ) for cross-sectional studies^{21,22}. The Cochrane tool assessed bias across key domains including randomization, intervention adherence, missing data, outcome measurement, and selective reporting, categorizing studies as low risk, high risk, or raising some concerns. The NOS evaluated cohort studies on population selection, comparability, and outcome measures, scoring quality as low (0–4), moderate (5 to 7), or high (>=8). The AHRQ assessed cross-sectional studies with 11 items scored dichotomously; total scores indicated low (0–3), moderate (4–7), or high quality (>7).

Data synthesis

Results were not pooled due to heterogeneity in study population, intervention, methods, data and context. Instead, we presented a narrative synthesis of the findings from included studies. Summaries of cost-effectiveness and costs items were reported for each study. To facilitate comparability, costs reported in various base years and currency were converted to 2022 US dollars using Consumer Price Index (CPI) and Purchasing Power Parity (PPP) conversion factors from the Organization for Economic Co-operation and Development (OECD) database (<https://www.oecd.org/en.html>), including¹⁶. The formula used for this conversion is as follows:

$$\text{Cost in US} = \frac{\text{Cost}_{\text{Original year}} * \left(\frac{\text{CPI}_{2022}}{\text{CPI}_{\text{Original Year}}} \right)}{\text{PPP Conversion Factor}_{2022}}$$

RESULTS

Study selection and quality assessment

The database search initially yielded 15,610 records, of which 3348 duplicates were removed, resulting in 12,262 publications for title and abstract screening (detailed in eTable 1–4). After screening, 158 studies met inclusion criteria for full-text review; 12 could not be retrieved, leaving 146 full texts for evaluation. Of these, 67 were excluded after full text reading, leaving 79 for final inclusion (Fig. 1)^{5,11,12,23–97}. Reasons for exclusion are presented in eTable 5.

Among the included articles, 69 (69/79, 87.3%) were model-based studies. The majority (62/69, 89.9%) were rated as high quality^{11,23,26,27,29,30,32–39,41–48,50,53–64,66–82,84,85,87,89,91–93,95–97}, while seven (7/69, 10.1%) were categorized as low quality but retained for their valuable contributions^{24,25,28,40,51,52,65}. The remaining 10 trials-based studies (10/79, 12.7%) was distributed as follows: 50.0% (5/10) were high-quality cross-sectional studies^{31,86,88,90,94}; 30.0% (3/10) were moderate-quality cross-sectional studies^{49,83,98}; 10.0% (1/10) was a moderate-quality cohort study¹²; and 10.0% (1/10) was an RCT with some concerns⁵ (eTable 6).

Study characteristics

Study designs and perspectives. The majority (69/79, 87.3%) used model-based evaluations, with 50 (63.3%) conducting cost-effectiveness or cost-utility analyses—28 (35.4%) were cost-effectiveness studies and only one cost-utility analysis (eTable 7).

Regarding cost perspectives, 20 studies (25.3%) did not specify any perspective. The most common perspectives reported were healthcare (26/79; 32.9%), followed by societal (13/79, 16.5%), health system (9/79, 11.4%), public payer (8/79, 10.1%), and one commercial payer perspective (eTable 7).

Study locations. The included studies covered 21 countries or regions. China (18/79, 22.8%) had the highest number of publications, followed by the US (16/79, 20.3%). Canada, Japan, and the UK each contributed 5 studies (6.3%).

Screening tools. LDCT was the most used tool, with usage steadily increasing since 2011. The integration of AI with LDCT emerged in 2022, and both the EarlyCDT-Lung test and polygenic risk score (PRS) were introduced alongside LDCT in 2024. Conventional CT and CXR usage remained low and stable after 2011. The diversity of screening tools increased substantially between 2014 and 2022, peaking in 2024 (Fig. 2).

Economic analyses methodologies. Almost all studies (78/79, 98.7%) reported their economic methods. Markov decision models were most common, used in 29 (37.2%) studies^{23,28,32,38,39,41,44,48,53,54,56,57,90}. Algebraic models (10.3%)^{24,31,40,47,65,74,84,87}, decision tree models (10.3%)^{25,26,59,60,68,69,72,85}, and direct calculations (11.5%)^{11,12,49,83,86,89,90,94,98} are similar represented (eFig. 1).




Fig. 1 Flowchart of the literature search and exclusion of studies.




Fig. 2 Frequency of lung cancer screening tools over time. AI: artificial intelligence; LDCT: low-dose computed tomography; PRS: polygenic risk score; CT: computed tomography; CXR: chest X-ray.

Cohort and populations. A total of 31 studies (39.2%) reported cohort characteristics for economic analyses^{5,11,23,30–34,39–41,43,44,47,52,53,55,56,59,60,63,64,66,98}, encompassing 13 LC screening cohorts from eight countries, all focused on smokers. The NLST (USA) and NELSON (Netherlands) cohorts were most frequently cited. The earliest cohort was the Early Lung Cancer Action Project (ELCAP) in 1992 (USA), and the most recent was the International Lung Screening Trial (ILST) in 2017 (Canada). LDCT was the predominant screening tool; notably, the UK's Early Detection of Cancer of the Lung Scotland (ECLS) study incorporated LDCT with blood-based biomarker testing (See eTable 8 for more details).

Participation and adherence. Nine studies have explored the impact of participation rates on the cost-effectiveness of LC

screening, yet their findings are inconsistent^{28,34,36,42,56,78,79,84,96}. Among them, two studies concluded that reduced adherence diminishes cost-effectiveness^{56,96}, while six reported that variations in adherence have minimal or no influence on cost-effectiveness^{28,34,42,78,79,84}. Additionally, one study suggested that lower participation rates may make screening more cost-effective for men³⁶.

Risk prediction models. Only 10 studies (12.7%) reported use of risk prediction models to identify high-risk populations for screening^{31–33,41,45,47,52,56,78,90}. The PLCO_{M2012} model was most common (3 studies)^{33,47,78}. Publicly available prediction tools, including Pan-Canadian Study web-based LC risk prediction tool³¹ and the Liverpool Lung Project tool⁴⁵, were used in two studies

each. Two studies leveraged high-risk population prediction models developed based on Chinese LC screening cohorts^{41,56}.

Cost items by perspective. Cost items reported in evaluations from different perspectives were categorized into ten groups: invitation and promotion, equipment and operational, diagnosis and assessment, imaging examination, report interpretation, follow-up tests, advanced diagnostics, treatment, complications, and other related costs. The healthcare perspective included the most comprehensive range of cost components (eTable 9–14).

Cost-effectiveness outcomes. The included studies reported ICERs for three outcomes: QALY, LYG, death averted. Among the 79 studies included, 59 (74.7%) assessed the cost-effectiveness of LDCT versus no screening, while 8 (10.1%) compared LDCT to CXR. Two studies (2.5%) examined AI combined with LDCT (AI&LDCT) for LC screening (Fig. 2). Notably, one study found that AI&LDCT was cost-saving, reporting a negative ICER of \$68/QALY versus LDCT alone⁹⁷. Given the heterogeneity of the outcome measures, we synthesized only those studies comparing LDCT to no screening with reported ICERs.

Among studies comparing LDCT screening with no screening, 14 reported ICER, calculated as cost per QALY gained (in US \$)^{5,23,42,47,50,66,67,70,73,75,76}. ICERs ranged from \$8376 to \$200,921 per QALY across different age groups and smoking status, with 90.3% (28/31) of screening strategies showing cost-effective. Generally, older populations exhibit lower ICERs, suggesting greater cost-effectiveness. Higher-risk groups, characterized by longer or heavier smoking histories, tended to have lower ICERs (Table 1). Five studies reported ICERs, calculated as cost per LYG (in US\$) among smokers, with values varying between \$5214 and \$364,763 per LYG^{5,48,67,82,90,96} (eTable 15).

Four studies reported variations in ICER across different age groups and screening frequencies^{39,48,50,64}. The most cost-effective screening frequency depended on population risk profiles. For example, among daily smokers aged 50–74, annual screening (\$12,613/QALY) was more cost-effective than biennial screening (\$23,374/QALY). In contrast, for individuals with high asbestos exposure in the same age group, biennial screening is favored over annual screening (Fig. 3A).

Two studies reported ICER in US\$ per LYG by gender, reporting lower cost-effectiveness in women than men for equivalent population and screening frequencies. Biennial screening was more cost-effective than annual screening for the same screening age group. The ICER for annual screening in men aged 55–75 was \$656,019/LYG versus \$41,567/LYG for biennial screening (eFig. 2A). One study reported the economic analysis results of ICER in US\$ per death averted by gender³⁶. Similar to the LYG results, LC screening is more cost-effective for men than for women within the same screening population and frequency. Additionally, biennial screening is more cost-effective than annual screening within the same age group. The ICER for annual screening in men aged 55–85 is \$604,658, while for biennial screening in the same age group, it is \$366,440 (eFig. 2B).

Four studies compared the cost-effectiveness of LC screening across guidelines, with ICER ranging from \$8328/QALY to \$112,700/QALY^{34,46,77,93}. The NELSON and China guidelines consistently showed favorable cost-effective. In contrast, the Preventive Services Task Force (USPSTF) guideline had the highest ICER (Fig. 3B). Three studies reporting ICER in US\$ per LYG similarly found NELSON more cost-effective than NLST (eFig. 3)^{34,42,46}.

DISCUSSION

This systematic review synthesizes evidence from 79 studies across 21 countries, providing an updated and comprehensive assessment of the cost-effectiveness of LC screening strategies.

We found that LDCT remains the primary and most cost-effective approach for LC screening, especially among older adults and high-risk smokers. Cost-effectiveness of LDCT varied by country, screening frequency, and risk criteria, with protocols based on the NELSON and China guidelines yielding the most favorable results. Alternative screening tools such as chest X-ray was less frequently evaluated and generally less cost-effective. Economic evidence for emerging modalities, including AI-enhanced screening, remains limited. To support future research and policy, we compiled a comprehensive set of components essential for economic analyses of LC screening from multiple perspectives.

LC screening is generally more cost-effective among populations with elevated risk factors, such as a history of smoking, older age, and male sex, as evidenced by lower ICERs^{36,37}. This trend is likely driven by the higher smoking prevalence and increased LC risk observed in men³. High-risk groups—including individuals with chronic obstructive pulmonary disease (COPD), longer smoking histories, greater smoking intensity, and current smokers as opposed to former smokers—derive the greatest economic benefit from screening^{7,82,93}. Consequently, there is a growing emphasis on integrating smoking cessation interventions alongside screening programs in order to improve both health outcomes and overall cost-effectiveness, although the added costs of these interventions necessitate careful consideration in economic analyses^{3,99}. However, evidence on the cost-effectiveness of LC screening for individuals with COPD is still lacking^{3,7,99}. More recently, the use of risk prediction models and the implementation of tailored screening intervals have emerged as promising strategies for optimizing the targeting of high-risk individuals and enhancing cost-effectiveness^{34,56,78}. However, the generalizability and external validity of these risk models, as well as risk-stratified screening approaches, remain to be fully established, particularly across diverse populations^{100–103}. For example, while most studies report greater cost-effectiveness of screening among men, epidemiological evidence from East Asia indicates a higher incidence of LC among non-smoking women, and some analyses have reported lower ICERs in this group compared with men^{1,3}. Whether LC screening consistently provides greater economic benefit among female non-smokers in East Asia remains unclear and warrants further investigation. Several studies have demonstrated that delaying the initiation age for LC screening generally reduces ICERs, thereby enhancing the economic efficiency of screening programs^{23,73,93,96}. This improvement is primarily attributed to the increased LC risk with advancing age, which results in greater health benefits from screening^{1,104}. However, extending the upper age limit for screening beyond 75 years yields limited marginal improvements in cost-effectiveness⁹³. Evidence indicates that ICERs tend to increase when screening continues in populations older than 75, reflecting diminished marginal health benefits and elevated healthcare costs⁹³. These findings highlight the need for careful evaluation of the benefits and costs of LC screening in individuals over 75 years and suggest that more targeted approaches may be warranted to optimize resource utilization in this age group.

The impact of screening compliance on cost-effectiveness remains unclear due to inconsistent findings across studies. Most modeling studies suggest that low participation rates have limited influence on cost-effectiveness^{28,34,42,78,79,84}. For example, Whynes et al., argue that if both costs and health gains fall with decreased participation, the ICER remain unchanged⁸⁴. However, in scenarios where fixed costs for infrastructure and administration are substantial, reduced uptake can lead to diminished cost-effectiveness by increasing the average cost per screened participant. These considerations highlight the importance of maximizing program uptake and minimizing fixed overheads to ensure efficient allocation of resources in real-world screening projects.

Table 1. The cost-effectiveness of LDCT screening versus no screening as measured by ICER (US\$/QALY).


Author	Study design	Quality score	Country	Perspective	Age	Smoking status	ICER (US \$/QALY)
AL ²³	Model- based	4	Netherlands	Healthcare	50–60*#	Smokers or ex-smokers who smoked more than 30 years at least 15 cigarettes per day, with no more than 10 years since smoking cessation	19,550
Black ⁵	Trial- based	Some concerns	United States	Societal	50–70*		21,059
Goffin ⁴²	Model- based	4	Canada	Healthcare	55–74*	Smoking history of at least 30 pack-years	110,494
Hinde ⁴⁷	Model- based	4	United Kingdom	Health system	55–74*	30 pack-year smoking history	59,194
Jaine ⁵⁰	Model- based	4	New Zealand	Health system	55–74*	Smoked and PLCO ₂₀₁₂ a 6- year lung cancer risk of $\geq 1.51\%$	18,446
Pan ⁶⁶	Model- based	4	United Kingdom	Healthcare	50–74*	With a smoking history of at least 30 pack years, and (if a former smoker) having quit within last 15 years	55,654
Pan ⁶⁷	Model- based	4	Greece	Healthcare	50–74*	With smoking history	8376
Rózsa ⁷⁰	Model- based	4	Hungary	Healthcare	50–74*	Heavy smokers	8869
Sun ⁷³	Model- based	4	China	Societal	50–74*	Smoking exposure of at least 25 pack-years	50,511
					40–76*	>20 pack- years, where a pack- year refers to 20 cigarettes smoked every day for 1 year	18,340
					45–76*		17,071
					50–76*		16,022
					55–76*#		15,217
					60–76*		15,702
Ten ⁷⁵ (1)	Model- based	4	Austria	Healthcare	50–74*	Current or former smokers (those who had quit ≤ 10 years ago) who had smoked >15 cigarettes a day for >25 years or >10 cigarettes a day for >30 years)	39,678
Ten ⁷⁶ (2)	Model- based	4	Portugal	Healthcare	50–74*	With a smoking history	10,376
Wade ⁸²	Model- based	4	Australia	Health System	55–74	Smoking history of at least 30 pack-years	200,921
Zhao ⁹⁶	Model- based	4	China	Societal	50–74*	With smoking history	37,614
					55–74*		30,079
					60–74*		24,458
					65–74*		21,391
					70–74*#		20,275
Zhang ⁹⁴	Model- based	4	China	Healthcare	65–74*	30 pack-years	24,706
					65–79*		24,861
					40–79	20 pack-years	46,772
					45–79*		38,654
					50–79*		32,494
					55–79*#		28,587
					60–79*		26,376
					65–74*		25,111
					65–79*		25,344

ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, PLCO prostate, lung, colorectal, and ovarian cancer screening trial. Costs are reported in 2022 US.

*A cost-effective screening strategy.

#The most cost-effective screening strategy.

A



B




Fig. 3 Cost-effectiveness of lung cancer screening. **A** Cost-effectiveness of lung cancer screening by age group in smoker. **B** Cost-effectiveness of lung cancer screening across guideline. ICER represents incremental cost-effectiveness ratio. Costs are reported in 2022 US\$. NLST: the National Lung Screening Trial; CMS: the Centers for Medicare & Medicaid Services; USPSTF: U.S. Preventive Services Task Force; NELSON: the Netherlands Leuven Screening Onderzoek.

This review emphasizes the emerging role of AI in LC screening and its potential to improve cost-effectiveness. AI integration can enhance various aspects of the screening workflow, including radiation dose reduction, improve lung nodule detection, personalized screening intervals, and the identification of incidental findings^{3,105}. Notably, one included study found that AI&LDCT was cost-saving compared to LDCT alone, underscoring its economic potential. The integration of AI into ultra-low-dose CT imaging has the potential to markedly reduce radiation exposure, thereby improving adherence to screening programs and ultimately influencing the economic evaluation of LC screening¹³. By improving sensitivity and accuracy of diagnosis, AI may reduce false positives and unnecessary interventions, thereby lowering costs and alleviating patient burden^{3,13,14}. Additionally, AI has the capability to detect and classify incidental findings in LDCT examinations, such as coronary artery calcification and emphysema, can add additional health value to screening programs³. However, current economic analyses seldom account for the

equipment and maintenance costs of AI systems. A reduction of these costs would likely lower total expenses and improve screening cost-effectiveness. However, as AI has not been widely implemented in practice, its real-world impact on cost-effectiveness is still uncertain. Given the limited evidence available—only two studies examined AI in this context—future comprehensive economic analyses are warranted to fully assess the cost-effectiveness of AI-assisted LC screening.

Unlike AI-assisted diagnosis, both blood tests and PRS identify individuals at high risk for LC through biomarkers, thereby impacting the cost-effectiveness of screening strategies^{69,96}. Blood-based screening emerges as the most cost-effective alternative compared to either no screening or LDCT alone, and reducing its cost would further enhance its cost-effectiveness value⁶⁹. In contrast, the PRS-based conjunctive strategy has not been found cost-effective, primarily because it may restricts screening to a smaller subgroup of high-risk individuals and therefore fails to yield additional life-years gained over LDCT

screening alone⁹⁶. Therefore, although lowering the cost of PRS testing may improve its economic profile, the prospect of achieving cost-effectiveness with PRS-based strategies remains uncertain and warrants further research.

Screening recommendations significantly influence the cost-effectiveness of LC screening^{1–3,7}. Existing studies have compared the cost-effectiveness of various strategies, including NLST, NELSON, USPSTF and Centers for Medicare & Medicaid Services (CMS)^{34,46,77}. Both Australian and Dutch studies have shown that the NELSON trial exhibits greater cost-effectiveness compared to the NLST^{46,77}. This superiority is largely attributable to NELSON's use of volume doubling time (VDT) for nodule management, which yield a substantially lower false positive rate (1.2% for NELSON vs. 23.3% for NLST)⁷⁷. The higher false positive rate in NLST leads to increased unnecessary diagnostic procedures, increasing costs and patient burden^{3,56,68,97}. Additionally, NELSON identified a significantly higher proportion of early-stage lung cancers compared to NLST, which results in greater projected gains in QALYs and LYG^{2,6,77}. These findings support the adoption of more precise nodule management strategies, as exemplified by NELSON, to enhance both clinical and economic outcomes in LC screening.

STRENGTHS AND LIMITATIONS

To our knowledge, this is the most comprehensive systematic review of economic evaluations and costing studies of LC screening, and is the first to include research on screening tools beyond LDCT, including AI-assisted methods and PRS. It also marks the first comprehensive synthesis comparing the cost-effectiveness of LC screening across populations recommended by different guidelines. Additionally, the review systematically categorizes potential cost items involved in LC screening from various cost perspectives for the first time. Summarizing cost items across different perspectives can assist policymakers in better managing expenses and making informed decisions. We acknowledge, however, that the field is rapidly evolving and continued updated reviews will remain important.

There are several limitations to this systematic review. Firstly, although we have made efforts to minimize heterogeneity across studies from different years and countries, methodological differences inevitably remain. Therefore, the results should be interpreted with caution. Specifically, variations in model types reflect differences in the underlying formulas, structural assumptions, and parameter choices used to estimate costs and outcomes. Analytic perspective influences which cost components are included in the analysis. The cost year accounts for adjustments related to inflation. The cost-effectiveness threshold represents the maximum expenditure a country is willing to make for additional health benefits, and this value typically varies according to a country's economic context. Secondly, most studies were conducted in high-income countries, the design of existing screening strategies, target populations, and associated costs can all vary by country, potentially limiting the generalizability of findings to specific settings. Thirdly, the review may be susceptible to publication bias, potentially leading to an overestimation of the benefits associated with LC screening. Further research is needed in low- and middle-income countries (LMICs) to address these gaps and enhance the applicability of evidence across diverse contexts.

CONCLUSION

In this systematic review of, LDCT was the predominant modality and generally found to be cost-effective within national thresholds. However, its cost-effectiveness was strongly influenced by the population risk profile—including age, sex, and smoking history—as well as the choice of screening guidelines and

research perspectives. Evidence for newer approaches, such as AI and biomarkers, is limited and needs further study. Few economic analyses exist for LMICs, where screening is not yet common. We strongly recommend that future work prioritize three critical areas: assessing the cost-effectiveness of emerging technologies like AI and biomarkers; evaluating risk-based screening in real-world settings; and generating robust, context-specific economic analyses for LMICs. This is essential to guide effective and equitable global implementation of lung cancer screening.

DATA AVAILABILITY

All data generated or analyzed during this study are included in this published article.

Received: 21 June 2025; Accepted: 12 January 2026;

Published online: 20 January 2026

REFERENCES

1. Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F. & Heist, R. S. Lung cancer. *Lancet (London, England)* **398**, 535–554 (2021).
2. de Koning, H. J. et al. Reduced lung-cancer mortality with volume CT Screening in a randomized trial. *The New England journal of medicine* **382**, 503–513 (2020).
3. Adams, S. J. et al. Lung cancer screening. *Lancet (London, England)* **401**, 390–408 (2023).
4. Dizon, D. S. & Kamal, A. H. Lung cancer screening guidelines: smoking matters, not quitting. *CA: a cancer journal for clinicians* **74**, 10–11 (2024).
5. Black, W. C. et al. Cost-effectiveness of CT screening in the national lung screening trial. *New England journal of medicine* **371**, 1793 (2014).
6. Aberle, D. R. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *The New England journal of medicine* **365**, 395–409 (2011).
7. Grover, H. et al. Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography. *Lung cancer (Amsterdam, Netherlands)* **170**, 20–33 (2022).
8. Puggina, A., Broumas, A., Ricciardi, W. & Boccia, S. Cost-effectiveness of screening for lung cancer with low-dose computed tomography: a systematic literature review. *European journal of public health* **26**, 168–175 (2016).
9. Snowsill, T. et al. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation. *Health technology assessment (Winchester, England)* **22**, 1–276 (2018).
10. Behr, C. M., Wolcherink, M. O. J., Ijzerman, M. J., Vliegenthart, R. & Koffijberg, H. Population-based screening using low-dose chest computed tomography: a systematic review of health economic evaluations. *Pharmacoeconomics* **41**, 395–411 (2023).
11. Pertile, P. et al. Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy. *Cost effectiveness and resource allocation* **13**, 15 (2015).
12. Dominioni, L. et al. Cost of a population-based programme of chest x-ray screening for lung cancer. *Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace* **79**, 67–72 (2013).
13. Huang, S., Yang, J., Shen, N., Xu, Q. & Zhao, Q. Artificial intelligence in lung cancer diagnosis and prognosis: Current application and future perspective. *Seminars in cancer biology* **89**, 30–37 (2023).
14. Li, Y., Wu, X., Yang, P., Jiang, G. & Luo, Y. Machine learning for lung cancer diagnosis, treatment, and prognosis. *Genomics, proteomics & bioinformatics* **20**, 850–866 (2022).
15. Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Journal of clinical epidemiology* **134**, 178–189 (2021).
16. Pinheiro, M. B. et al. Economic evaluations of fall prevention exercise programs: a systematic review. *British journal of sports medicine* **56**, 1353–1365 (2022).
17. Mohan, G. & Chattopadhyay, S. Cost-effectiveness of leveraging social determinants of health to improve breast, cervical, and colorectal cancer screening: a systematic review. *JAMA oncology* **6**, 1434–1444 (2020).
18. Drummond, M. F. & Jefferson, T. O. Guidelines for authors and peer reviewers of economic submissions to the BMJ. *The BMJ Economic Evaluation Working Party. BMJ (Clinical research ed.)* **313**, 275–283 (1996).
19. Sterne, J. A. C. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ (Clinical research ed.)* **366**, l4898 (2019).
20. Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *European Journal of Epidemiology* **25**, 603–605 (2010).

21. Rostom A., Dubé C. & Cranney A. Celiac Disease. Rockville (MD): Agency for Healthcare Research and Quality (US). Appendix D. Quality Assessment Forms. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK35156/> (2004).
22. Fan, Z. et al. The prevalence of hip osteoarthritis: a systematic review and meta-analysis. *Arthritis research & therapy* **25**, 51 (2023).
23. Al Khayat, M., Eijssink, J. F. H., Postma, M. J., van de Garde, E. M. W. & van Hultst, M. Cost-effectiveness of screening smokers and ex-smokers for lung cancer in the Netherlands in different age groups. *The European journal of health economics* **23**, 1221–1227 (2022).
24. Asakura, K., Hanamura, K., Sone, S., Li, F. & Takizawa, M. Economic aspects in mass screening for lung cancer with mobile CT scanner. *Japanese Journal of Lung Cancer* **39**, 381–388 (1999).
25. Baba, Y., Takahashi, M., Tominguchi, S. & Kiyota, S. Cost-effectiveness decision analysis of mass screening for lung cancer. *Academic radiology* **5**, S344–S346 (1998).
26. Beinfeld, M. T., Wittenberg, E. & Gazelle, G. S. Cost-effectiveness of whole-body CT screening. *Radiology* **234**, 415–422 (2005).
27. Cadham, C. J. et al. Cost-effectiveness of smoking cessation interventions in the lung cancer screening setting: a simulation study. *Journal of the National Cancer Institute* **113**, 1065–1073 (2021).
28. Caro, J. J., Klittich, W. S. & Strauss, G. Could chest X-ray screening for lung cancer be cost-effective?. *Cancer* **89**, 2502–2505 (2000).
29. Castleberry, A. W., Smith, D., Anderson, C., Rotter, A. J. & Grannis, F. W. Jr Cost of a 5-year lung cancer survivor: symptomatic tumour identification vs proactive computed tomography screening. *British journal of cancer* **101**, 882–896 (2009).
30. Chirikos, T. N., Hazelton, T., Tockman, M. & Clark, R. Screening for lung cancer with CT: a preliminary cost-effectiveness analysis. *Chest* **121**, 1507–1514 (2002).
31. Cressman, S. et al. Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada. *Journal of Thoracic Oncology* **9**, 1449–1458 (2014).
32. Cressman, S. et al. The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency. *Journal of Thoracic Oncology* **12**, 1210–1222 (2017).
33. Cressman, S. et al. Economic impact of using risk models for eligibility selection to the International lung screening Trial. *Lung cancer (Amsterdam, Netherlands)* **176**, 38–45 (2023).
34. Criss, S. D. et al. Cost-effectiveness analysis of lung cancer screening in the united states: a comparative modeling study. *Annals of internal medicine* **171**, 796–804 (2019).
35. Diaz, M. et al. Health and economic impact at a population level of both primary and secondary preventive lung cancer interventions: a model-based cost-effectiveness analysis. *Lung cancer (Amsterdam, Netherlands)* **159**, 153–161 (2021).
36. Du, Y. et al. Cost-effectiveness of lung cancer screening by low-dose CT in China: a micro-simulation study. *Journal of the National Cancer Center* **2**, 18–24 (2022).
37. Du, Y. et al. Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study. *European journal of cancer (Oxford, England : 1990)* **135**, 121–129 (2020).
38. Esmaeili, M. H. et al. Cost-effectiveness analysis of lung cancer screening with low-dose computed tomography in an Iranian high-risk population. *Journal of medical screening* **28**, 494–501 (2021).
39. Gendarme, S. et al. Cost-effectiveness of an organized lung cancer screening program for asbestos-exposed subjects. *Cancers* **14**, 4089 (2022).
40. Gendarme, S. et al. Economic impact of lung cancer screening in France: a modeling study. *Revue des maladies respiratoires* **34**, 717–728 (2017).
41. Geng, Q., Lin, X., Feng, C., Liu, Y. & Zhang, S. Cost-Utility Analysis of Lung Cancer Screening for Non-Smokers in Henan Based on Absolute Risk. *Bulletin of Chinese Cancer* **33**, 373–381 (2024).
42. Goffin, J. R. et al. Cost-effectiveness of lung cancer screening in Canada. *JAMA oncology* **1**, 807–813 (2015).
43. Goffin, J. R. et al. Biennial lung cancer screening in Canada with smoking cessation outcomes and cost-effectiveness. *Lung cancer (Amsterdam, Netherlands)* **101**, 98–103 (2016).
44. Gomez-Carballo, N., Fernandez-Soberon, S. & Rejas-Gutierrez, J. Cost-effectiveness analysis of a lung cancer screening programme in Spain. *European Journal of Cancer Prevention* **31**, 235–244 (2022).
45. Griffin, E. et al. Lung cancer screening by low-dose computed tomography: a cost-effectiveness analysis of alternative programmes in the UK using a newly developed natural history-based economic model. *Diagnostic and prognostic research* **4**, 20 (2020).
46. Harpaz, S. B. et al. Updated cost-effectiveness analysis of lung cancer screening for Australia, capturing differences in the health economic impact of NELSON and NLST outcomes. *British journal of cancer* **128**, 91–101 (2023).
47. Hinde, S. et al. The cost-effectiveness of the Manchester 'lung health checks', a community-based lung cancer low-dose CT screening pilot. *Lung cancer (Amsterdam, Netherlands)* **126**, 119–124 (2018).
48. Hofer, F., Kauczor, H.-U. & Stargardt, T. Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: a modelling approach. *Lung cancer (Amsterdam, Netherlands)* **124**, 189–198 (2018).
49. Huang, F. et al. The feasibility and cost-effectiveness of implementing mobile low-dose computed tomography with an AI-based diagnostic system in underserved populations. *BMC cancer* **25**, 345 (2025).
50. Jaine, R., Kvizhinadze, G., Nair, N. & Blakely, T. Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand. *Lung cancer (Amsterdam, Netherlands)* **144**, 99–106 (2020).
51. Kanarkiewicz, M. et al. Cost-effectiveness analysis of lung cancer screening with low-dose computerised tomography of the chest in Poland. *Contemporary oncology (Poznan, Poland)* **19**, 480–486 (2015).
52. Kim, D. D. et al. Targeted incentive programs for lung cancer screening can improve population health and economic efficiency. *Health Affairs* **38**, 60–67 (2019).
53. Kim, J. et al. Cost utility analysis of a pilot study for the Korean lung cancer screening project. *Cancer research and treatment* **54**, 728–736 (2022).
54. Kowada, A. Cost-effectiveness and health impact of lung cancer screening with low-dose computerised tomography for never smokers in Japan and the United States: a modelling study. *BMC pulmonary medicine* **22**, 19 (2022).
55. Kumar, V. et al. Risk-targeted lung cancer screening: a cost-effectiveness analysis. *Annals of internal medicine* **168**, 161–169 (2018).
56. Liu, Y. et al. Risk-based lung cancer screening in heavy smokers: a benefit-harm and cost-effectiveness modeling study. *BMC medicine* **22**, 3 (2024).
57. Mahadevia, P. J. et al. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. *Jama* **289**, 313–322 (2003).
58. Manser, R. et al. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. *Lung cancer (Amsterdam, Netherlands)* **48**, 171–185 (2005).
59. Marshall, D., Simpson, K. N., Earle, C. C. & Chu, C. W. Potential cost-effectiveness of one-time screening for lung cancer (LC) in a high risk cohort. *Lung cancer (Amsterdam, Netherlands)* **32**, 227–236 (2001).
60. Marshall, D., Simpson, K. N., Earle, C. C. & Chu, C. W. Economic decision analysis model of screening for lung cancer. *European journal of cancer (Oxford, England : 1990)* **37**, 1759–1767 (2001).
61. McLeod, M., Sandiford, P., Kvizhinadze, G., Bartholomew, K. & Crengle, S. Impact of low-dose CT screening for lung cancer on ethnic health inequities in New Zealand: a cost-effectiveness analysis. *BMJ open* **10**, e037145 (2020).
62. McMahon, P. M. et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. *Journal of thoracic oncology* **6**, 1841–1848 (2011).
63. Nagy, B. et al. The budget impact of lung cancer screening with low-dose computed tomography. *Orvosi hetilap* **162**, 952–959 (2021).
64. Nagy, B. et al. Shall we screen lung cancer with low-dose computed tomography? cost-effectiveness in Hungary. *Value in health regional issues* **34**, 55–64 (2023).
65. Okamoto, N. Cost-effectiveness of lung cancer screening in Japan. *Cancer* **89**, 2489–2493 (2000).
66. Pan, X. et al. Cost-effectiveness of volume computed tomography in lung cancer screening: a cohort simulation based on nelson study outcomes. *Journal of medical economics* **27**, 27–38 (2023).
67. Pan, X. et al. Lung cancer screening with volume computed tomography is cost-effective in Greece. *PLoS one* **20**, e0316351 (2025).
68. Rajabi, T. et al. Cost-effectiveness of lung cancer screening with low-dose computed tomography: comparing hungarian screening protocols with the US NLST. *Cancers* **16**, <https://doi.org/10.3390/cancers16172933> (2024).
69. Robles-Zurita, J. A., McMeekin, N., Sullivan, F., Mair, F. S. & Briggs, A. Health economic evaluation of lung cancer screening using a diagnostic blood test: the early detection of cancer of the lung scotland (ECLS). *Current oncology (Toronto, Ont.)* **31**, 3546–3562 (2024).
70. Róza, P. et al. Economic evaluation of low-dose computed tomography for lung cancer screening among high-risk individuals - evidence from Hungary based on the HUNCHEST-II study. *BMC health services research* **24**, 1537 (2024).
71. Sheu, C. C. et al. Cost-effectiveness of low-dose computed tomography screenings for lung cancer in high-risk populations: a markov model. *World journal of oncology* **15**, 550–561 (2024).
72. Shmueli, A. et al. Cost-effectiveness of baseline low-dose computed tomography screening for lung cancer: the Israeli experience. *Value in health* **16**, 922–931 (2013).
73. Sun, C. et al. Determining cost-effectiveness of lung cancer screening in urban Chinese populations using a state-transition Markov model. *BMJ open* **11**, e046742 (2021).
74. Tabata, H. et al. Cost-effectiveness of the introduction of low-dose CT screening in Japanese smokers aged 55 to 74 years old. *Hiroshima journal of medical sciences* **63**, 13–22 (2014).

75. Ten Berge, H. et al. Shall we screen lung cancer with volume computed tomography in austria? a cost-effectiveness modelling study. *Cancers* **16**, 2623 (2024).
76. Ten Berge, H. et al. Cost-effectiveness of lung cancer screening with volume computed tomography in Portugal. *Journal of comparative effectiveness research* **13**, e240102 (2024).
77. Ten Berge, H. et al. Cost-effectiveness analysis of a lung cancer screening program in the Netherlands: a simulation based on NELSON and NLST study outcomes. *Journal of medical economics* **27**, 1197–1211 (2024).
78. Tomonaga, Y., de Nijs, K., Bucher, H. C., de Koning, H. & Ten Haaf, K. Cost-effectiveness of risk-based low-dose computed tomography screening for lung cancer in Switzerland. *International journal of cancer* **154**, 636–647 (2024).
79. Tomonaga, Y. et al. Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking—a modelling study. *Lung cancer (Amsterdam, Netherlands)* **121**, 61–69 (2018).
80. Treskova, M. et al. Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting. *BMC medicine* **15**, 162 (2017).
81. Villanti, A. C., Jiang, Y., Abrams, D. B. & Pyenson, B. S. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. *PLoS one* **8**, e71379 (2013).
82. Wade, S. et al. Estimating the cost-effectiveness of lung cancer screening with low-dose computed tomography for high-risk smokers in Australia. *Journal of Thoracic Oncology* **13**, 1094–1105 (2018).
83. Wang, Y., Wang, L. & Wang, X. A cancer screening survey among urban residents in Hangzhou city: costeffectiveness and cost-utility analysis. *China Journal of Public Health* **36**, 12–15 (2020).
84. Whynes, D. K. Could CT screening for lung cancer ever be cost effective in the United Kingdom?. *Cost effectiveness and resource allocation* **6**, 5 (2008).
85. Wisnivesky, J. P., Mushlin, A. I., Sicherman, N. & Henschke, C. The cost-effectiveness of low-dose CT screening for lung cancer - preliminary results of baseline screening. *Chest* **124**, 614–621 (2003).
86. Wu, C. H. et al. Estimating time and transportation costs associated with lung cancer screening and diagnostic lung procedures in Taiwan: a cross-sectional survey in a medical centre. *BMJ open* **13**, e070647 (2023).
87. Xia, C., Xu, Y., Li, H., He, S. & Chen, W. Benefits and harms of polygenic risk scores in organised cancer screening programmes: a cost-effectiveness analysis. *The Lancet Regional Health - Western Pacific* **44**, 101012 (2024).
88. Yang, Q. et al. Results and cost-effectiveness analysis of lung cancer screening for urban residents in Xuzhou from 2014 to 2019. *Chinese Journal of Cancer Prevention and Treatment* **29**, 463–467 (2022).
89. Yang, S. C. et al. Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan. *Lung cancer (Amsterdam, Netherlands)* **108**, 183–191 (2017).
90. Yang, Y. et al. Efficiency of lung cancer screening in early diagnosis and treatment program among community residents in Nanshan district, Shenzhen city: a cross-sectional and 2-year follow-up survey. *China Journal of Public Health* **40**, 1312–1317 (2024).
91. Yuan, J. et al. Cost effectiveness of lung cancer screening with low-dose CT in heavy smokers in China. *Cancer prevention research (Philadelphia, Pa.)* **15**, 37–44 (2022).
92. Zeng, X., Zhou, Z., Luo, X. & Liu, Q. Lung cancer screening with low-dose computed tomography: national expenditures and cost-effectiveness. *Frontiers in public health* **10**, 977550 (2022).
93. Zhang, T. et al. Cost-effectiveness analysis of risk factor-based lung cancer screening program by low-dose computer tomography in current smokers in China. *Cancers* **15**, 4445 (2023).
94. Zhang, X. et al. Results of lung cancer screening among urban residents aged 45–74 years old in Haikou City from 2019 to 2021 and cost-effectiveness analysis. *Bulletin of Chinese Cancer* **33**, 492–497 (2024).
95. Zhao, Z. et al. Cost-effectiveness of lung cancer screening using low-dose computed tomography based on start age and interval in China: modeling study. *JMIR public health and surveillance* **8**, e36425 (2022).
96. Zhao, Z. et al. A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score. *BMC cancer* **24**, 73 (2024).
97. Ziegelmayer, S., Graf, M., Makowski, M., Gawlitza, J. & Gassert, F. Cost-effectiveness of artificial intelligence support in computed tomography-based lung cancer screening. *Cancers* **14**, 1729 (2022).
98. Marshall, H. M. et al. Cost of screening for lung cancer in Australia. *Internal medicine journal* **49**, 1392–1399 (2019).
99. Lam, S. et al. Current and future perspectives on computed tomography screening for lung cancer: a roadmap from 2023 to 2027 from the international association for the study of lung cancer. *Journal of thoracic oncology* **19**, 36–51 (2024).
100. Choi, E. et al. Risk model-based lung cancer screening and racial and ethnic disparities in the US. *JAMA oncology* **9**, 1640–1648 (2023).
101. Toumazis, I., Bastani, M., Han, S. S. & Plevritis, S. K. Risk-based lung cancer screening: a systematic review. *Lung cancer (Amsterdam, Netherlands)* **147**, 154–186 (2020).
102. Wang, F. et al. Risk-stratified approach for never- and ever-smokers in lung cancer screening: a prospective cohort study in China. *American journal of respiratory and critical care medicine* **207**, 77–88 (2023).
103. Yang, J. J. et al. Lung cancer risk prediction models for Asian ever-smokers. *Journal of thoracic oncology* **19**, 451–464 (2024).
104. Kuang, Z. et al. Global, regional, and national burden of tracheal, bronchus, and lung cancer and its risk factors from 1990 to 2021: findings from the global burden of disease study 2021. *EClinicalMedicine* **75**, 102804 (2024).
105. Fan, Z. et al. XGBoost-SHAP-based interpretable diagnostic framework for knee osteoarthritis: a population-based retrospective cohort study. *Arthritis research & therapy* **26**, 213 (2024).

ACKNOWLEDGEMENTS

We would like to acknowledge the State Key Laboratory of Respiratory Disease for its valuable advice.

AUTHOR CONTRIBUTIONS

ZJF and MQZ contributed equally as co-first authors. ZJF and MQZ conceptualized the study and developed the protocol. ZJF, ZYG and MQZ designed the search strategy and conducted the literature search. HTL, PYG, YZ, BZ, LYH and XQZ performed data screen and extraction. TTF, MTL, XJR, NJR and CLZ assessed data quality. ZJF and MQZ conducted data analysis. WXW, CH and JHL provided expert supervision during data extraction and analysis. ZJF and MQZ drafted the initial manuscript. HTL, PYG, YZ, BZ, LYH, WXW, CH and JHL critically revised the manuscript for important intellectual content and supervised data interpretation.

FUNDING

This research was funded by Start-up Research Grant of the University of Macau (SRG2025-00031-FHS). The funder played no role in study design, data collection, analysis and interpretation of data, or the writing of this manuscript.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41533-026-00482-w>.

Correspondence and requests for materials should be addressed to Wenxi Wang, Chun Hao or Jinghua Li.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2026